Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.

29 Sep 2009

Dialysis patients often not told about transplant options, Newspaper finds

"Thousands of kidney patients in the United States start dialysis without first being told of kidney transplants that would be cheaper and lead to longer lives, according to a four-month newspaper investigation published Sunday," The Associated Press reports.

28 Sep 2009

Pros and cons of the estimated Glomerular Filtration Rate

As many as 26 million Americans live with chronic kidney disease (CKD) and according to the National Institutes of Health (NIH), at least 10.4 million (or 40%) don't even know they have it. Enter the estimated Glomerular Filtration Rate (eGFR), which has become the preferred method for identifying people with CKD.

23 Sep 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Researchers to focus on abnormal fetal growth and chronic kidney disease

The National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $3.5 million to study epigenetic changes - chemical modifications of genes caused by stress, diet or other environmental influences - and how they contribute to human diseases and biological processes.

18 Sep 2009

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

18 Sep 2009

NIH to fund grants for epigenetic research

The National Institutes of Health announced today that it will fund 22 grants on genome-wide studies of how epigenetic changes -- chemical modifications to genes that result from diet, aging, stress, or environmental exposures -- define and contribute to specific human diseases and biological processes.

17 Sep 2009

DaVita achieves target fistula usage rate in Virginia

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized in the state of Virginia for reaching the End Stage Renal Disease (ESRD) Network's patient quality improvement goal.

16 Sep 2009

Long-term implications of severe acute kidney problems

Hospitalized patients who experience acute kidney problems that require dialysis are at increased risk of receiving chronic dialysis once discharged, but do not have an increased risk of death, according to a study in the September 16 issue of JAMA.

16 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

DaVita Kidney Awareness Run/Walks increases CKD awareness

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), kicks off the DaVita Kidney Awareness Run/Walks(TM) - a 10-city series of 5K events raising funds and awareness of CKD across the nation -- on Sept. 13 at Stapleton Central Park in Denver.

14 Sep 2009

End stage renal disease can be delayed by early identification of CKD

Early identification of individuals with chronic kidney disease (CKD) can delay the onset of end stage renal disease (ESRD) and the need for chronic dialysis treatments. The incidence of CKD continues to grow, and early identification and intervention are critical to manage this costly disease.

11 Sep 2009

FDA removes clinical hold on HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.

10 Sep 2009

DaVita offers individualized treatment options for students with kidney disease

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), supports dialysis patients' education by offering individualized treatment options based on optimal patient care standards and social circumstances.

10 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009

PROTECT clinical study aimed at the assessment of rolofylline effects

Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.

2 Sep 2009

Study reveals that baking soda benefits patients with advanced chronic kidney disease

A daily dose of sodium bicarbonate—baking soda, already used for baking, cleaning, acid indigestion, sunburn, and more—slows the decline of kidney function in some patients with advanced chronic kidney disease (CKD), reports an upcoming study in the Journal of the American Society of Nephrology (JASN).

2 Sep 2009

Davita Chairman is one of 100 Most Powerful People in Healthcare

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), today announced that Modern Healthcare Magazine, one of the nation's leading health care industry publications, named Kent Thiry, Chairman and CEO for DaVita(R), as one of the 100 Most Powerful People in Healthcare in 2009.

1 Sep 2009

DaVita's nocturnal dialysis treatment allows patients to dialyze in-clinic while sleeping overnight

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), today announced its nocturnal dialysis patient population has reached a milestone, with 1,000 patients having received this life-saving treatment in more than 90 DaVita(R) centers around the nation. DaVita has one of the largest nocturnal patient populations in the country.

28 Aug 2009

DaVita to present three abstracts on Peritoneal Dialysis at the ISPD meeting

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research(R), today announced that it will present three abstracts at the 3rd North American Chapter meeting of the International Society for Peritoneal Dialysis (ISPD) on August 27-29 in Vancouver, British Columbia.

26 Aug 2009